When Do the Effects of Wegovy Start, and What Happens First?

Step 1, Days 1 to 14: the earliest signs that something is changing

The first thing most people report is not a number on the scales but a shift in their relationship with food. Meals feel satisfying sooner. The pull toward a second helping fades. Some people notice this after their very first injection; for others it takes until the second or third week. These early appetite signals are the medicine beginning to activate GLP-1 receptors in the brain and gut, slowing the rate at which the stomach empties and turning down the volume on hunger hormones.

Weight loss at this stage is usually modest, and that is expected. The 0.25 mg starting dose is not a treatment dose; it exists to let your body adjust. A question our prescribers hear regularly is whether the medicine is working if the scales barely move at this point. The answer is almost certainly yes, appetite suppression this early is the mechanism doing its job. Gastrointestinal discomfort (nausea, loose stools, burping, reflux) is common in week one and two. It peaks, then fades for most people. Keeping the pen in the fridge door as a prompt for a consistent weekly injection day helps build the routine that keeps the timeline on track. You can read more about how semaglutide works at a clinical level on our semaglutide overview page.

The question of exactly when you start feeling the effects of Wegovy is one we cover in more detail separately, because individual variation here is wide.

Step 2, Weeks 4 to 16: dose increases and the first measurable weight changes

Once tolerability is established, a prescriber moves the dose upward, typically through 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the 2.4 mg maintenance dose. Each increase may bring a brief return of mild GI symptoms, this is normal and usually brief. It is also at these steps that hunger suppression deepens noticeably.

Weight loss during this phase becomes easier to track. Research published in the New England Journal of Medicine as the STEP 1 trial showed that participants lost an average of around 6% of body weight by week 16 at escalating doses. That figure represents an average across thousands of participants; individual results vary considerably depending on starting weight, diet, and activity levels.

This is also the phase where the practical routine matters most. Eating a little less, choosing protein-rich foods, and staying well hydrated helps the medicine do more. Weight-loss medicines are licensed alongside a reduced-calorie diet and increased activity for exactly this reason. Our Wegovy treatment page covers what the full treatment programme looks like.

Step 3, Months 4 to 18: maintenance dose and sustained loss

At 2.4 mg, the maintenance dose for most people, weight loss continues to accumulate. The STEP 1 trial's 68-week result was an average reduction of around 15% of body weight. Some participants lost considerably more; some less. The trajectory is rarely a straight line: loss tends to be steeper in the first several months and then levels to a slower, steadier pace as the body adapts.

If you are considering where to start, the timing question around starting Wegovy is worth reading before your consultation. Factors like life events, travel, and any planned surgery affect when it makes sense to begin.

The NHS semaglutide medicines page provides an accessible summary of what to expect during treatment and when to contact a healthcare professional. For most people, the 12-month mark is when the full picture of what Wegovy can do for them becomes clear. Some continue losing weight; others have reached a stable lower weight that their body is maintaining.

Cost is a practical question at this stage too. If you want to understand how private treatment pricing works and what it covers, our guide to accessing Wegovy in the UK explains the options without any pressure to act.

When effects take longer than expected, and when to say something

A minority of people reach the maintenance dose and find the effect on appetite or weight is smaller than hoped. This is not failure; it reflects genuine biological variation in how different people respond to GLP-1 receptor agonists. NICE guidance notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing is reviewed clinically. That review is a conversation, not an automatic stop, and your prescriber leads it. If you are taking other medications alongside treatment, our page on using naltrexone and Wegovy together is worth reading before your next consultation.

There are also side effects that should prompt contact sooner rather than later. Severe stomach pain that spreads to the back and does not settle, especially with vomiting, needs same-day medical attention because of the known, infrequent risk of acute pancreatitis with GLP-1 medicines. Gallbladder symptoms, signs of dehydration from persistent GI illness, and any allergic reaction are other reasons to seek help promptly. Report suspected side effects through the MHRA Yellow Card scheme. If you have specific concerns, our aftercare team is available seven days a week.

Wegovy's effects develop on their own schedule, shaped partly by the titration timeline and partly by your physiology. Patience in the first two months tends to pay off. If you would like a prescriber to review whether Wegovy is the right option for you, start your free consultation with nume's clinical team today.